{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:09:59Z","timestamp":1785769799510,"version":"3.56.0"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"15","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,10]]},"abstract":"<jats:p>\n                    This study aimed to investigate the role of the plasma lipid species in the progression from chronic hepatitis B (CHB) infection to cirrhosis. We conducted 2-sample Mendelian randomization (MR) and genome-wide mediation analyses to explore the causal relationship between CHB and cirrhosis, focusing on lipid species as potential mediators. The inverse variance weighted method was used as the primary analytical approach, supported by complementary estimators. Sensitivity analyses \u2013 including Cochran\u2019s\n                    <jats:italic toggle=\"yes\">Q<\/jats:italic>\n                    test, MR-Egger intercept test, of Mendelian randomization pleiotropy residual sum and outlier global test, and leave-one-out analysis \u2013 were performed to assess robustness, heterogeneity, and horizontal pleiotropy. We found a significant positive association between CHB and cirrhosis (odds ratio\u2005=\u20051.206; 95% CI: 1.080 to 1.346;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.001). Among 179 common lipid species analyzed, genetic predispositions for 29 were significantly associated with CHB and 4 with cirrhosis. Mediation analysis identified 2 lipid species \u2013 ceramide (d40:2) and phosphatidylcholine (18:2_20:4) \u2013 as potential mediators in the causal pathway from CHB to cirrhosis. Ceramide (d40:2) mediated 11.65% of the effect (mediation effect: 0.022; 95% CI: 0.002 to 0.049;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.037), while phosphatidylcholine (18:2_20:4) mediated 6.62% (mediation effect: 0.012; 95% CI: \u22120.0003 to 0.030;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.072). Overall, this study provides genetic evidence supporting the causal role of CHB in the development of cirrhosis and highlights ceramide (d40:2) and phosphatidylcholine (18:2_20:4) as key mediators in this process.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000048252","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:00:35Z","timestamp":1775840435000},"page":"e48252","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Plasma lipidome mediates the causal effect of chronic hepatitis B on cirrhosis: A Mendelian randomization study"],"prefix":"10.1097","volume":"105","author":[{"given":"Biao","family":"Xiao","sequence":"first","affiliation":[{"name":"Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qixiang","family":"Song","sequence":"additional","affiliation":[{"name":"Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenggang","family":"Wang","sequence":"additional","affiliation":[{"name":"Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[{"name":"Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[{"name":"Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boqi","family":"Li","sequence":"additional","affiliation":[{"name":"Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghai","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Third Xiangya Hospital, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelin","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Civil and Environmental Engineering, Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewelina","family":"Krol","sequence":"additional","affiliation":[{"name":"Laboratory of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Khouri","sequence":"additional","affiliation":[{"name":"Laboratory of Precision Medicine and Public Health, Gon\u00e7alo Moniz Institute, Oswaldo Cruz Foundation, Salvador, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"De Clercq","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute of Hepatology and Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8852-034X","authenticated-orcid":false,"given":"Guangdi","family":"Li","sequence":"additional","affiliation":[{"name":"Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260410","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","article-title":"Global epidemiology of cirrhosis - aetiology, trends and predictions.","volume":"20","author":"Huang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R2-20260410","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","article-title":"Global burden of hepatitis B virus: current status, missed opportunities and a call for action.","volume":"20","author":"Hsu","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R3-20260410","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ijid.2022.06.017","article-title":"Trends in the disease burden of HBV and HCV infection in China from 1990-2019.","volume":"122","author":"Yue","year":"2022","journal-title":"Int J Infect Dis"},{"key":"R4-20260410","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S2468-1253(22)00050-4","article-title":"Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review.","volume":"7","author":"Alberts","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R5-20260410","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(08)60383-9","article-title":"Liver cirrhosis.","volume":"371","author":"Schuppan","year":"2008","journal-title":"Lancet"},{"key":"R6-20260410","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.addr.2020.06.027","article-title":"The hepatic lipidome: from basic science to clinical translation.","volume":"159","author":"Ten Hove","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"R7-20260410","doi-asserted-by":"crossref","first-page":"100479","DOI":"10.1016\/j.jhepr.2022.100479","article-title":"Lipid alterations in chronic liver disease and liver cancer.","volume":"4","author":"Paul","year":"2022","journal-title":"JHEP Rep"},{"key":"R8-20260410","doi-asserted-by":"crossref","first-page":"1436827","DOI":"10.3389\/fendo.2024.1436827","article-title":"Role of plasma metabolome in mediating the effect of plasma lipidome on NAFLD: a Mendelian randomization study.","volume":"15","author":"Zheng","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R9-20260410","doi-asserted-by":"crossref","first-page":"436","DOI":"10.4254\/wjh.v12.i8.436","article-title":"Lipidomics in non-alcoholic fatty liver disease.","volume":"12","author":"Kartsoli","year":"2020","journal-title":"World J Hepatol"},{"key":"R10-20260410","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11306-017-1215-x","article-title":"Plasma lipidomics identifies novel biomarkers in patients with hepatitis B virus-related acute-on-chronic liver failure.","volume":"13","author":"Wang","year":"2017","journal-title":"Metabolomics"},{"key":"R11-20260410","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1515\/cclm-2023-0798","article-title":"Targeted quantitative lipidomic uncovers lipid biomarkers for predicting the presence of compensated cirrhosis and discriminating decompensated cirrhosis from compensated cirrhosis.","volume":"62","author":"Zeng","year":"2024","journal-title":"Clin Chem Lab Med"},{"key":"R12-20260410","first-page":"748","article-title":"Dyslipidemia and impaired liver function biomarkers in patients with hepatitis B liver cirrhosis.","volume":"18","author":"Shoaib","year":"2023","journal-title":"J Taibah Univ Med Sci"},{"key":"R13-20260410","doi-asserted-by":"crossref","first-page":"e0187","DOI":"10.1097\/HC9.0000000000000187","article-title":"Dysregulation of lipid metabolism in the pseudolobule promotes region-specific autophagy in hepatitis B liver cirrhosis.","volume":"7","author":"Pu","year":"2023","journal-title":"Hepatol Commun"},{"key":"R14-20260410","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12944-017-0437-2","article-title":"Serum lipid profile as a marker of liver impairment in hepatitis B Cirrhosis patients.","volume":"16","author":"Arain","year":"2017","journal-title":"Lipids Health Dis"},{"key":"R15-20260410","doi-asserted-by":"crossref","first-page":"a041302","DOI":"10.1101\/cshperspect.a041302","article-title":"Mendelian Randomization.","volume":"12","author":"Birney","year":"2021","journal-title":"Cold Spring Harbor Perspect Med"},{"key":"R16-20260410","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1093\/hmg\/ddu328","article-title":"Mendelian randomization: genetic anchors for causal inference in epidemiological studies.","volume":"23","author":"Davey Smith","year":"2014","journal-title":"Hum Mol Genet"},{"key":"R17-20260410","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10654-021-00757-1","article-title":"Mendelian randomisation for mediation analysis: current methods and challenges for implementation.","volume":"36","author":"Carter","year":"2021","journal-title":"Eur J Epidemiol"},{"key":"R18-20260410","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10654-020-00622-7","article-title":"Mendel\u2019s laws, Mendelian randomization and causal inference in observational data: substantive and nomenclatural issues.","volume":"35","author":"Davey Smith","year":"2020","journal-title":"Eur J Epidemiol"},{"key":"R19-20260410","doi-asserted-by":"crossref","first-page":"67","DOI":"10.12997\/jla.2019.8.2.67","article-title":"Mendelian randomization analysis in observational epidemiology.","volume":"8","author":"Lee","year":"2019","journal-title":"J Lipid Atherosclerosis"},{"key":"R20-20260410","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41588-021-00931-x","article-title":"A cross-population atlas of genetic associations for 220 human phenotypes.","volume":"53","author":"Sakaue","year":"2021","journal-title":"Nat Genet"},{"key":"R21-20260410","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1038\/s41588-021-00954-4","article-title":"A generalized linear mixed model association tool for biobank-scale data.","volume":"53","author":"Jiang","year":"2021","journal-title":"Nat Genet"},{"key":"R22-20260410","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.1038\/s41467-023-42532-8","article-title":"Genome-wide association analysis of plasma lipidome identifies 495 genetic associations.","volume":"14","author":"Ottensmann","year":"2023","journal-title":"Nat Commun"},{"key":"R23-20260410","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1186\/s12967-024-05704-8","article-title":"Explore genetic susceptibility association between viral infections and Guillain-Barr\u00e9 syndrome risk using two-sample Mendelian randomization.","volume":"22","author":"Kong","year":"2024","journal-title":"J Transl Med"},{"key":"R24-20260410","doi-asserted-by":"crossref","first-page":"e34408","DOI":"10.7554\/eLife.34408","article-title":"The MR-Base platform supports systematic causal inference across the human phenome.","volume":"7","author":"Hemani","year":"2018","journal-title":"eLife"},{"key":"R25-20260410","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature09534","article-title":"A map of human genome variation from population-scale sequencing.","volume":"467","author":"Consortium","year":"2010","journal-title":"Nature"},{"key":"R26-20260410","doi-asserted-by":"crossref","first-page":"e1003288","DOI":"10.1371\/journal.pmed.1003288","article-title":"Genetics of height and risk of atrial fibrillation: a Mendelian randomization study.","volume":"17","author":"Levin","year":"2020","journal-title":"PLoS Med"},{"key":"R27-20260410","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/0962280210394459","article-title":"Using multiple genetic variants as instrumental variables for modifiable risk factors.","volume":"21","author":"Palmer","year":"2012","journal-title":"Stat Methods Med Res"},{"key":"R28-20260410","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/ije\/dyq151","article-title":"Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants.","volume":"40","author":"Pierce","year":"2011","journal-title":"Int J Epidemiol"},{"key":"R29-20260410","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/ije\/dyy262","article-title":"An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings.","volume":"48","author":"Sanderson","year":"2018","journal-title":"Int J Epidemiol"},{"key":"R30-20260410","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jama.2021.18236","article-title":"Strengthening the reporting of observational studies in epidemiology using mendelian randomization: the STROBE-MR statement.","volume":"326","author":"Skrivankova","year":"2021","journal-title":"JAMA"},{"key":"R31-20260410","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10654-015-0011-z","article-title":"Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors.","volume":"30","author":"Consortium","year":"2015","journal-title":"Eur J Epidemiol"},{"key":"R32-20260410","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1002\/sim.7221","article-title":"A framework for the investigation of pleiotropy in two\u2010sample summary data Mendelian randomization.","volume":"36","author":"Bowden","year":"2017","journal-title":"Stat Med"},{"key":"R33-20260410","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41588-018-0099-7","article-title":"Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases.","volume":"50","author":"Verbanck","year":"2018","journal-title":"Nat Genet"},{"key":"R34-20260410","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10654-017-0255-x","article-title":"Interpreting findings from Mendelian randomization using the MR-Egger method.","volume":"32","author":"Burgess","year":"2017","journal-title":"Eur J Epidemiol"},{"key":"R35-20260410","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1186\/s12967-023-04368-0","article-title":"Phosphodiesterase and psychiatric disorders: a two-sample Mendelian randomization study.","volume":"21","author":"Jiang","year":"2023","journal-title":"J Transl Med"},{"key":"R36-20260410","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/ije\/dyr233","article-title":"Two-step epigenetic Mendelian randomization: a strategy for establishing the causal role of epigenetic processes in pathways to disease.","volume":"41","author":"Relton","year":"2012","journal-title":"Int J Epidemiol"},{"key":"R37-20260410","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/s42255-019-0134-8","article-title":"Metabolic messengers: ceramides.","volume":"1","author":"Summers","year":"2019","journal-title":"Nat Metab"},{"key":"R38-20260410","doi-asserted-by":"crossref","first-page":"42710","DOI":"10.1038\/srep42710","article-title":"Serum lipid alterations identified in chronic hepatitis B, hepatitis B virus-associated cirrhosis and carcinoma patients.","volume":"7","author":"Wu","year":"2017","journal-title":"Sci Rep"},{"key":"R39-20260410","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.7150\/ijms.75820","article-title":"Association between serum sphingolipids and necroinflammation of liver tissue pathology in chronic hepatitis B.","volume":"19","author":"Ren","year":"2022","journal-title":"Int J Med Sci"},{"key":"R40-20260410","doi-asserted-by":"crossref","first-page":"9806","DOI":"10.3390\/ijms23179806","article-title":"Serum ceramide species are associated with liver cirrhosis and viral genotype in patients with hepatitis C infection.","volume":"23","author":"H\u00f6ring","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R41-20260410","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1053\/j.gastro.2023.02.023","article-title":"Sphingolipids are depleted in alcohol-related liver fibrosis.","volume":"164","author":"Thiele","year":"2023","journal-title":"Gastroenterology"},{"key":"R42-20260410","doi-asserted-by":"crossref","first-page":"364","DOI":"10.2174\/187152012800228689","article-title":"Hepatocarcinogenesis and ceramide\/cholesterol metabolism.","volume":"12","author":"Morales","year":"2012","journal-title":"Anticancer Agents Med Chem"},{"key":"R43-20260410","doi-asserted-by":"crossref","first-page":"3689375","DOI":"10.1155\/2017\/3689375","article-title":"Association between plasmatic ceramides profile and AST\/ALT ratio: C14:0 ceramide as predictor of hepatic steatosis in adolescents independently of obesity.","volume":"2017","author":"Maldonado-Hern\u00e1ndez","year":"2017","journal-title":"Can J Gastroenterol Hepatol"},{"key":"R44-20260410","doi-asserted-by":"crossref","first-page":"5676","DOI":"10.3390\/ijms22115676","article-title":"Ceramide and related molecules in viral infections.","volume":"22","author":"Beckmann","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R45-20260410","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3390\/jcm10040792","article-title":"Roles of ceramides in non-alcoholic fatty liver disease.","volume":"10","author":"Hajduch","year":"2021","journal-title":"J Clin Med"},{"key":"R46-20260410","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.3390\/ijms18122550","article-title":"Aberrant lipid metabolism in hepatocellular carcinoma revealed by liver lipidomics.","volume":"18","author":"Li","year":"2017","journal-title":"Int J Mol Sci"},{"key":"R47-20260410","doi-asserted-by":"crossref","first-page":"e171267","DOI":"10.1172\/JCI171267","article-title":"Blood-derived lysophospholipid sustains hepatic phospholipids and fat storage necessary for hepatoprotection in overnutrition.","volume":"133","author":"Chin","year":"2023","journal-title":"J Clin Investig"},{"key":"R48-20260410","doi-asserted-by":"crossref","first-page":"8161","DOI":"10.3390\/ijms25158161","article-title":"Serum phosphatidylcholine species 32:0 as a biomarker for liver cirrhosis pre- and post-hepatitis C virus clearance.","volume":"25","author":"Weigand","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R49-20260410","doi-asserted-by":"crossref","first-page":"393","DOI":"10.23736\/S2724-5985.21.03066-7","article-title":"Treatment with phosphatidylcholine of patients with nonalcoholic fatty liver disease: a prospective pilot study.","volume":"68","author":"Abenavoli","year":"2022","journal-title":"Minerva Gastroenterol"},{"key":"R50-20260410","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1080\/17512433.2022.2121700","article-title":"Effectiveness of polyene phosphatidylcholine and its combination with other drugs in patients with liver diseases based on real-world research.","volume":"15","author":"Li","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R51-20260410","doi-asserted-by":"crossref","first-page":"842098","DOI":"10.3389\/fmed.2022.842098","article-title":"A Multicenter real-world study evaluating the hepatoprotective effect of polyene phosphatidylcholine against chronic hepatitis B.","volume":"9","author":"Xu","year":"2022","journal-title":"Front Med"},{"key":"R52-20260410","first-page":"1425","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (version 2022).","volume":"11","author":"You","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"R53-20260410","doi-asserted-by":"crossref","first-page":"e70185","DOI":"10.1002\/jmv.70185","article-title":"The effect of HBV therapy on glycemic control in HBV-infected patients with diabetes: a 90-day multicenter study.","volume":"97","author":"Liu","year":"2025","journal-title":"J Med Virol"},{"key":"R54-20260410","doi-asserted-by":"crossref","first-page":"e0201325","DOI":"10.1128\/mbio.02013-25","article-title":"AntiviralDB: an expert-curated database of antiviral agents against human infectious diseases.","volume":"16","author":"Huang","year":"2025","journal-title":"mBio"},{"key":"R55-20260410","doi-asserted-by":"crossref","first-page":"e28635","DOI":"10.1002\/jmv.28635","article-title":"Poor glycemic control in type-2 diabetic patients infected with hepatitis B: a retrospective propensity-matched study.","volume":"95","author":"Cai","year":"2023","journal-title":"J Med Virol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048252","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:21:42Z","timestamp":1785766902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":55,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048252","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"2025-08-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}